Brentuximab vedotin followed by ABVD +/− radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

Benzer Materyaller

• Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
  Yazar:: Gandolfi, Letizia, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients
  Yazar:: Zinzani, Pier Luigi, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
  Yazar:: Stefoni, Vittorio, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
  Yazar:: Zinzani, Pier Luigi, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
  Yazar:: Connors, Joseph M., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)